WHAT IS SEEKED TO BE PATENTED AS NOVEL & UNOBVIOUS IN LETTERS PATENT OF THE UNITED STATES IS:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)
29. (Canceled)
30. (Canceled)
31. (Canceled)
32. (Canceled)
33. (Canceled)
34. (Canceled)
35. (Canceled)
36. (Canceled)
37. (Canceled)
38. (Canceled)
39. (Canceled)
40. (Canceled)
41. (Canceled)
42. (Canceled)
43. (Canceled)
44. (Canceled)

45. (Canceled)
46. (Canceled)
47. (Canceled)
48. (Canceled)
49. (Canceled)
50. (Canceled)
51. (Canceled)
52. (Canceled)
53. (Canceled)
54. (Canceled)
55. (Canceled)
56. (Canceled)
57. (Canceled)
58. (Canceled)
59. (Canceled)
60. (Canceled)
61. (Canceled)
62. (Canceled)
63. (Canceled)
64. (Canceled)
65. (Canceled)
66. (Canceled)
67. (Canceled)
68. (Canceled)
69. (Canceled)
70. (Canceled)
71. (Canceled)
72. (Canceled)
73. (Canceled)
74. (Canceled)
75. (Canceled)
76. (Canceled)
77. (Canceled)
78. (Canceled)
79. (Canceled)
80. (Canceled)
81. (Amended) An in vivo method of imaging a cancer of epithelial origin or cells expressing a polypeptide having the antibody binding specificity of the about 46 Kd differentiation Human Milk Fat Globule (HMFG) antigen, comprising

administering to a subject suspected of being afflicted with the cancer or carrying the cells an amount of a detectably labeled or unlabeled specifically targeted antibody, comprising a monoclonal antibody selectively binding a 46 Kd MW HMFG differentiation antigen that has an antigen affinity constant about 10^{10}-10^{5} M^{-1}, and an agent comprising a detectable label, the antibody and the agent being operatively linked to one another, under conditions effective to deliver the antibody to target cells of epithelial origin carrying at least a portion of the 46Kd MW HMFG differentiation antigen in the subject's body to form antibody-cell antigen complexes;

administering to the subject a detectably labeled agent that binds the antibody at a site other than the 46 kDalton HMFG polypeptide binding site if the antibody is unlabeled; and

detecting the presence of a label in the subject's body.

82. (Amended) The method of claim 81, wherein the antibody is administered intravenously, intraperitoneally, intracavitarily, intra-tumor, intramuscularly, or into the lymphatic system.

83. (Amended) The method of claim 81, wherein the labeled agent comprises a fuorescent or radiolabeled agent.

84. (Amended) The method of claim 81, wherein

the antibody comprises an unlabeled antibody; and

the labeled agent comprises a labeled anti-antibody immunoglobulin, antibody binding fragment thereof, protein A, or Protein C.

85. (Amended) The method of claim 81, further comprising upon label detection the delivery of a therapeutic agent to target cancerous cells or cells of epithelial origin by

binding a therapeutic agent to the antibody of claim 81, at a site other than its antigen binding site;

administering to the subject a therapeutically effective amount of the antibody-bound therapeutic agent under conditions effective for the antibody to deliver the agent to the target cells; and

allowing the antibody to bind to the target cells, and the therapeutic agent to exert its effect on the cells.

86. (Canceled)

87. (Canceled)

88. (New) The method of claim 81, wherein the labeled agent comprises a radionucleide, a fluorescent label, an enzyme or biotin.

89. (New) The method of claim 81, wherein the labeled agent is detected as a conjugate.

90. (New) The method of claim 89, wherein the antibody is conjugated to avidin, streptavidin, or a magnetic bead.

91. (New) The method of claim 81, wherein the antibody comprises a monoclonal antibody.

92. (New) The method of claim 81, wherein the antibody is provided as a composition with a non -proteolytic carrier.

93. (New) The method of claim 92, wherein the carrier comprises a biologically acceptable carrier.

94. (New) The method of claim 93, wherein the carrier comprises a pharmaceutically acceptable carrier.

95. (New) The method of claim 85, wherein the therapeutic agent comprises a radionucleide, an immmunotoxin, or an enzyme.

96. (New) The method of claim 85, wherein the antibody-therapeutic agent is delivered as a conjugate.

97. (New) The method of claim 96, wherein the antibody-therapeutic agent is conjugated to avidin, streptavidin, or a magnetic bead.

98. (New) The method of claim 85, wherein the antibody-therapeutic agent comprises a monoclonal antibody.

99. (New) The method of claim 85, wherein antibody-therapeutic agent is provided as a composition with a non proteolytic carrier.

100. (New) The method of claim 99, wherein the antibody-therapeutic agent carrier comprises a biologically acceptable carrier.

101. (New) The method of claim 100, wherein the antibody-therapeutic agent carrier comprises a pharmaceutically acceptable carrier.